Compare CRVL & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRVL | TWST |
|---|---|---|
| Founded | 1987 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.0B |
| IPO Year | 1995 | 2018 |
| Metric | CRVL | TWST |
|---|---|---|
| Price | $52.90 | $47.18 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $48.75 |
| AVG Volume (30 Days) | 191.0K | ★ 903.7K |
| Earning Date | 02-03-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 1.53 | N/A |
| Revenue | ★ $895,589,000.00 | $376,572,000.00 |
| Revenue This Year | N/A | $18.91 |
| Revenue Next Year | N/A | $15.07 |
| P/E Ratio | $34.16 | ★ N/A |
| Revenue Growth | 12.61 | ★ 20.32 |
| 52 Week Low | $44.83 | $23.30 |
| 52 Week High | $117.70 | $57.88 |
| Indicator | CRVL | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 46.33 | 52.43 |
| Support Level | $50.51 | $41.69 |
| Resistance Level | $55.46 | $57.88 |
| Average True Range (ATR) | 1.83 | 2.73 |
| MACD | 0.26 | 0.12 |
| Stochastic Oscillator | 44.74 | 61.29 |
CorVel Corp applies technology including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. It partners with employers, third-party administrators, insurance companies, and government agencies in managing worker's compensation and health, auto, and liability services. The company's solutions combine integrated technologies with a human touch providing services that include claims management, bill review, preferred provider networks, utilization management, case management, pharmacy services, directed care, and medicare services.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.